Figure S3 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Xuyang Song,Robin Kate Kelley,Anis A. Khan,Nathan Standifer,Diansong Zhou,KyoungSoo Lim,Rajesh Krishna,Lu Liu,Kun Wang,Patricia McCoon,Alejandra Negro,Philip He,Megan Gibbs,John F. Kurland,Ghassan K. Abou-Alfa

crossref（2023）

引用 0|浏览12

暂无评分

摘要

Supplementary Figure S3. CFB of proliferating CD8+Ki67+ T cells vs predicted tremelimumab exposure (PD analysis population) in patients with lower and higher baseline CD8+Ki67+ T-cell counts

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要